
    
      To compare the efficacy and tolerability of Fulvestrant 500 mg with Exemestane 25 mg as first
      line endocrine therapy in postmenopausal women with oestrogen receptor positive HER2 negative
      advanced breast cancer who have relapsed on or after adjuvant non-aromatase inhibitor therapy
    
  